Adults with rare phosphate-wasting bone disorders face significant diagnostic delays and inconsistent treatment approaches worldwide, potentially leaving thousands suffering from preventable complications. These conditions cause severe bone pain, muscle weakness, and skeletal deformities by disrupting the body's ability to properly mineralize bone tissue.
The international survey captured experiences from 40 bone specialists across 24 countries managing over 1,000 adult patients with hypophosphataemic osteomalacia. X-linked hypophosphataemia affected 35% of cases, while tumor-induced osteomalacia accounted for 24%, and fibrous dysplasia with McCune-Albright syndrome represented 16%. Bone pain affected two-thirds of X-linked patients and nearly 90% of tumor-induced cases, while muscle weakness plagued similar proportions.
This data exposes critical gaps in our understanding of phosphate metabolism disorders that likely affect far more adults than currently recognized. Many patients with X-linked hypophosphataemia had already discontinued phosphate supplementation, suggesting either treatment failure or intolerable side effects from current therapeutic approaches. The variation in management strategies across countries indicates lack of standardized care protocols for these debilitating conditions. Given that these disorders often go undiagnosed for years while causing progressive skeletal damage, the survey highlights an urgent need for improved diagnostic criteria and treatment guidelines. The involvement of academic medical centers suggests these complex cases require specialized expertise, yet access to such care remains limited globally. This represents both a significant healthcare burden and an opportunity for targeted interventions to improve quality of life for affected adults.